ArticleBlood2020
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07690943 (A Clinical Study to Evaluate the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell Treatment in Prolonged SARS-CoV-2 Infected Patients), which is not on this map. Cited by 90 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Study to Evaluate the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell Treatment in Prolonged SARS-CoV-2 Infected Patients
Who cites it
90 citing papers in PubMed, 3 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- CAR Immunotherapy for the treatment of infectious diseases: a systematic review.Frontiers in immunology · 2024Pooled it
- A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2.Virus research · 2023Pooled it
- Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.Journal for immunotherapy of cancer · 2021Pooled it
- SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.Nature medicine · 2023Trial
- A Multiepitope Intranasal Adenoviral Vaccine Induces Robust Mucosal Immunity and Protection against SARS‑CoV‑2.Journal of nanobiotechnology · 2026Article
- Early Immunological Biomarkers for Personalized Treatment Selection in Severe COVID-19: Post Hoc Machine Learning Analysis of a Randomized Clinical Trial.JMIR medical informatics · 2026Article
- Systematic profiling of SARS-CoV-2 structural protein-specific T cell epitopes in Omicron infections following inactivated vaccination.iScience · 2026Article
- Expanding SARS-CoV-2 antigen targets beyond spike using a baculovirus expression system.Scientific reports · 2026Article
- Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunity.bioRxiv : the preprint server for biology · 2026Article
- The structure and function of membrane protein in coronavirus infection and its applications in the development of vaccines and therapeutic drugs.Frontiers in microbiology · 2026Review
- Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection.Frontiers in immunology · 2026Article
- Article
- Dual-antigen recognition iPSC-derived CAR-T cells for B-cell malignancies: establishment of a COVID-19 vaccine synergy strategy.Frontiers in cell and developmental biology · 2026Article
- Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy.Molecular therapy. Methods & clinical development · 2025Article
- Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.Frontiers in immunology · 2025Article
- Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.International journal of molecular sciences · 2024Article
- Article
- Review
- Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells.Molecular therapy. Methods & clinical development · 2024Article
- Review of flow cytometry as a tool for cell and gene therapy.Cytotherapy · 2024Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors at 5 institutions in 1 country.
Funding
Abstract
T-cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described in recovered patients, and may be important for immunity following infection and vaccination as well as for the development of an adoptive immunotherapy for the treatment of immunocompromised individuals. In this report, we demonstrate that SARS-CoV-2-specific T cells can be expanded from convalescent donors and recognize immunodominant viral epitopes in conserved regions of membrane, spike, and nucleocapsid. Following in vitro expansion using a good manufacturing practice-compliant methodology (designed to allow the rapid translation of this novel SARS-CoV-2 T-cell therapy to the clinic), membrane, spike, and nucleocapsid peptides elicited interferon-γ production, in 27 (59%), 12 (26%), and 10 (22%) convalescent donors (respectively), as well as in 2 of 15 unexposed controls. We identified multiple polyfunctional CD4-restricted T-cell epitopes within a highly conserved region of membrane protein, which induced polyfunctional T-cell responses, which may be critical for the development of effective vaccine and T-cell therapies. Hence, our study shows that SARS-CoV-2 directed T-cell immunotherapy targeting structural proteins, most importantly membrane protein, should be feasible for the prevention or early treatment of SARS-CoV-2 infection in immunocompromised patients with blood disorders or after bone marrow transplantation to achieve antiviral control while mitigating uncontrolled inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.